Synopsis In type 2 diabetes mellitus (T2DM), cardiovascular disease is the leading cause of morbidity and mortality. Therefore, reducing its burden is an important goal of antidiabetic medications (ADMs). Metformin is widely used as a first-line therapy due to its cardiovascular benefits. However, there is a lack of consensus among the clinicians in choosing the right ADM for patients who are intolerant of metformin or unable to achieve adequate glycemic control with metformin.
This week’s “ MED FACT ” discusses a retrospective, cohort study from JAMA, ‘ Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes ’, Dec 2018. Authors : O’Brien M J, Karam S L, Wallia A et al. Key Takeaways Clinicians may need to consider prescribing newer classes of ADMs more routinely after metformin due to their association with reduced…
